Concert Pharmaceuticals wins new patents on deuterium-modified compounds
Concert Pharmaceuticals, a clinical stage biotechnology company, has received its first patents from the US Patent and Trademark Office. These patents relate to specific compounds derived from Concert’s
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.